Antiviral treatment and liver‐related complications in hepatitis delta

Anika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, Janina Kirschner, Birgit Bremer, Patrick Lehmann, Svenja Hardtke, Katja Deterding, Kerstin Port, Max Westphal, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 22 October 2016 – Hepatitis delta virus (HDV) is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG‐IFNα) is effective in only 25%‐30% of patients and is associated with frequent side effects. The aim of this study was to analyze the clinical long‐term outcome of hepatitis delta in relation to different antiviral treatment strategies.

Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum

Xuehua Piao, Soh Yamazaki, Sachiko Komazawa‐Sakon, Sanae Miyake, Osamu Nakabayashi, Takeyuki Kurosawa, Tetsuo Mikami, Minoru Tanaka, Nico Van Rooijen, Masaki Ohmuraya, Akira Oikawa, Yuko Kojima, Soichiro Kakuta, Yasuo Uchiyama, Masato Tanaka, Hiroyasu Nakano – 22 October 2016 – Tissue‐resident macrophages and bone marrow (BM)‐derived monocytes play a crucial role in the maintenance of tissue homeostasis; however, their contribution to recovery from acute tissue injury is not fully understood.

Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Jennifer T. Wells, Carmen E. Landaverde, Barbara Evans, Anita Howe, Hsueh‐Cheng Huang, Jerry Jing Li, Peggy Hwang, Frank J. Dutko, Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber – 22 October 2016 – Direct‐acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different mechanisms may allow for shorter treatment durations that are effective across multiple genotypes.

Survival and cost‐effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER–Medicare database

Neehar D. Parikh, Vincent D. Marshall, Amit G. Singal, Hari Nathan, Anna S. Lok, Rajesh Balkrishnan, Vahakn Shahinian – 22 October 2016 – Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC). However, its effectiveness in patients with Child‐Pugh class B cirrhosis and any moderating effects of health system characteristics are unclear. We examined the survival and cost‐effectiveness associated with sorafenib in elderly patients with advanced HCC. We performed an analysis of Medicare beneficiaries with HCC diagnoses from 2007 to 2009.

Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay

Li Zhang, Zhihong Yang, Jocelyn Trottier, Olivier Barbier, Li Wang – 22 October 2016 – Bile acids (BAs) play critical physiological functions in cholesterol homeostasis, and deregulation of BA metabolism causes cholestatic liver injury. The long noncoding RNA maternally expressed gene 3 (MEG3) was recently shown as a potential tumor suppressor; however, its basic hepatic function remains elusive.

Human liver sinusoidal endothelial cells promote intracellular crawling of lymphocytes during recruitment: A new step in migration

Daniel A. Patten, Garrick K. Wilson, Dalan Bailey, Robert K. Shaw, Sirpa Jalkanen, Marko Salmi, Antal Rot, Chris J. Weston, David H. Adams, Shishir Shetty – 22 October 2016 – The recruitment of lymphocytes via the hepatic sinusoidal channels and positioning within liver tissue is a critical event in the development and persistence of chronic inflammatory liver diseases. The hepatic sinusoid is a unique vascular bed lined by hepatic sinusoidal endothelial cells (HSECs), a functionally and phenotypically distinct subpopulation of endothelial cells.

IL‐6 trans‐signaling is essential for the development of hepatocellular carcinoma in mice

Juri Bergmann, Miryam Müller, Niklas Baumann, Manuel Reichert, Carola Heneweer, Julia Bolik, Karsten Lücke, Sabine Gruber, Antonella Carambia, Susanne Boretius, Ivo Leuschner, Thomas Becker, Björn Rabe, Johannes Herkel, F. Thomas Wunderlich, Hans‐Willi Mittrücker, Stefan Rose‐John, Dirk Schmidt‐Arras – 22 October 2016 – Hepatocellular carcinoma (HCC) is one of the most frequent tumors worldwide with rising incidence. The inflammatory cytokine, interleukin‐6 (IL‐6), is a critical mediator of HCC development.

Expression of scavenger receptor‐AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis

Adam C. Labonte, Sun‐Sang J. Sung, Lucas T. Jennelle, Aditya P. Dandekar, Young S. Hahn – 22 October 2016 – The liver maintains an immunologically tolerant environment as a result of continuous exposure to food and bacterial constituents from the digestive tract. Hepatotropic pathogens can take advantage of this niche and establish lifelong chronic infections causing hepatic fibrosis and hepatocellular carcinoma. Macrophages (Mϕ) play a critical role in regulation of immune responses to hepatic infection and regeneration of tissue.

Antiviral treatment and liver‐related complications in hepatitis delta

Anika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, Janina Kirschner, Birgit Bremer, Patrick Lehmann, Svenja Hardtke, Katja Deterding, Kerstin Port, Max Westphal, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 22 October 2016 – Hepatitis delta virus (HDV) is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG‐IFNα) is effective in only 25%‐30% of patients and is associated with frequent side effects. The aim of this study was to analyze the clinical long‐term outcome of hepatitis delta in relation to different antiviral treatment strategies.

Subscribe to